Aboriginal and Torres Strait Islander people: Adult immunisations
Aboriginal and Torres Strait Islander peoples have higher rates of some vaccine preventable diseases. Some National Immunisation Program vaccines can be accessed at a younger age for people in this population group. The below table summarises the vaccines recommended for Aboriginal and Torres Strait Islander peoples by adult age groups:
Aboriginal people 70-79 years
Zoster (shingles) vaccineZostavax®
Funded for all 70-year-oldsFunded catch up extended until 31/10/2023 for all 71-79 year olds
Aboriginal people ≥50 years
Pneumococcal vaccinePrevenar 13®: from 50 yearsPneumovax 23®: 2-12 months laterPneumovax 23®: at least 5 years later
Aboriginal and Torres Strait Islander people: COVID-19 vaccination uptake
The COVID-19 vaccination report (27 April 2022) lists the percentage of people who have self-identified as Indigenous who have been vaccinated against COVID-19 by local government area (LGA). The percentages are broken down for individuals who have received 2 doses, and individuals who have received 3 or more doses. *It should be noted when interpreting the data, that COVID-19 vaccination is now recommended to be delayed by 3 months after a confirmed SARS-CoV-2 infection which may affect uptake.
mRNA vaccine dose interval: extended to 8 weeks
ATAGI recommends an 8-week interval between dose one and dose two for Pfizer and Moderna for people aged 5 years and older, particularly for males aged 12 to 39 years. The extended dose interval has been shown to improve the immune response to vaccination, may improve effectiveness, and may also reduce the risk of myocarditis and pericarditis.
The dose interval can be reduced (to a minimum of 3 weeks for Pfizer or 4 weeks for Moderna) for people at higher risk of severe COVID-19 (including older adults and people with underlying medical conditions), in an outbreak setting, or prior to international travel.
ATAGI flowchart: COVID-19 vaccine recommendation by age and population group
This flowchart (updated 2 May 2022) summarises the ATAGI recommendations relating to COVID-19 vaccines. It outlines the appropriate vaccine brand and doses that are recommended for each age and population group.
Defer COVID-19 vaccination for 3 months after SARS-CoV-2 infection
Vaccination is recommended to be deferred for at least 3 months after a confirmed SARS-CoV-2 infection for all COVID-19 vaccine doses, including booster doses. This updated advice reflects the lower risk of reinfection with the Omicron variant within the first 3 months following a confirmed infection, particularly if prior COVID-19 vaccine doses have been received.
This recommendation does not apply to other vaccines (for example, influenza vaccinations) which can continue to be administered as soon as a person recovers from acute infection.
RAT now acceptable for temporary vaccine exemption
Rapid antigen tests reported to the State reporting system are now considered acceptable proof of infection for the purposes of a temporary medical exemption to delay vaccination. The time frame for temporary deferral of vaccination following SARS-CoV-2 infection has been updated from 6 months to 4 months.
IFNAR1 Deficiency and serious adverse events following immunisation
IFNAR1 deficiency is a rare inherited condition affecting some people in Australia of Western Polynesian heritage including Tongan, Samoan, and Niuean people. The Chief Medical Officer has provided ATAGI information
On 27 April 2022 the TGA granted provisional determination for the Moderna bivalent COVID-19 vaccine “Spikevax Bivalent Zero/Omicron”. Moderna has developed a bivalent vaccine that includes the mRNA sequence encoding the spike protein of the Omicron variant of concern and the original Spikevax vaccine.
Provisional determination means that Moderna is now able to apply for provisional registration for the bivalent vaccine for active immunisation to prevent COVID-19, but does not guarantee approval of the application.
COVID-19 live stream update for GPs
COVID-19 vaccine live stream for GPs – key updates and live Q&A
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…
Seeking GP insight for HealthPathways Sydney improvement project Since its launch in March 2014, the HealthPathways Sydney program has developed nearly one thousand clinical HealthPathways and referral resources. The HealthPathways Sydney team are currently investigating how to make our processes for reviewing and updating content more efficient; ensuring that pathway…
Future of Home & Community Care Hybrid Conference The new Support at Home program and broader sector-wide reforms will have a significant impact on the way that Home and Community Care services are delivered and funded. You may have many questions over what the final model will look like, and…